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Aims: Assessment of the intensity of the JAK2 V617F mutation prev-
alence on the age and sex dependence using the model of the “second 
order phase transition’’.
Methods: The data base of the Krasnoyarsk branch of the National He-
matology Research Center from Jan 2012 to Feb 2019 examination has 
been used. The JAK2V617F allele burden was measured in whole blood 
samples by an allele-specific quantitative polymerase chain reaction us-
ing of the “Myeloskrin JAK2 kit’’ (Formula of gene ltd). The relationship 
between the q (rate of JAK2 V617F detection) and the 1/T indicator 
(“reverse age’’) in each age-old five-year cohort on 1154 men and 958 
women referred with suspicion of MPN was studied. The values of q2 
should be close to zero as according to the model of second order phase 
transitions for physical systems until reaching a certain critical patients 
age Tc and the relationship between the q2 and 1/T variables will be 
described by the equation q2 = a-b/T with an angular coefficient b char-
acterizing the increase in the intensity of the mutational burden with age 
after reaching the critical age Tc.
Results: Using of our model led to transforms the monotonous growth 
curve of mutation prevalence with age. The value of q2 is close to zero at 
high values of 1/T (young patients) and for smaller values of 1/T (more 
older age) the relationship between q2 and 1/T becomes linear (figure). 
The hypothesis of the statistical significance differences of regression for 
male and female was tested by Fisher test for the significance level a=5%. 
Hypothesis of the absence of differences between the two regressions is 
not rejected. The critical age of patients transition to the phase with a 
high risk of mutation development corresponds for male Tc = 48.8 years 
and for female Tc = 36.0 years. Intensity of further accumulation of the 
mutation burden in male b = 44.35 ± 12.86, in female b = 27.52 ± 4.57.
Summary/Conclusion: The “second order phase transitions model’’ 
it possible to introduce in the population analysis the indicators of 
the “critical age’’ T c and the intensity of accumulation of the burden 
of mutations b. This estimate are not significantly different for male 
and female for our sample. The calculated critical age turned out 
to be significantly lower than the median of the age of diagnosis 
of MPN (53 and 57 years). The proposed model will be useful for 
analyzing the characteristics of the population of MPN in different 
cohorts, as well as in different social and environmental conditions 
of life.
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Background: Pathogenesis in Philadelphia-negative Myeloprolifera-
tive Neoplasms (MPNs) is surely linked to genomic alterations in He-
matopoietic Stem Cells (HSCs), most of all on genes which can carry 
mutations referred to as driver mutations: JAK2, CALR and MPL. In-
flammation, neoangiogenesis and fibrosis are part of the clinical and 
biological picture of MPNs. Recent studies have hypotized a possible 
HSC-independent, active role of the Mesenchymal Stem Cells (MSCs) in 
the pathogenesis of these diseases.
Aims: Our aim is to characterize the molecular profile of bone marrow 
MSCs (BM-MSCs) of patients with diagnosis of MPNs to explore their 
possible contribution in the pathogenesis of the disease. In particular, we 
focused on the study of specific miRNA and mRNA already known in 
literature to be involved in processes of inflammation, neoangiogenesis 
and fibrosis in MPNs.
Methods: Primary cultures of BM-MSCs were obtained from bone mar-
row samples of patients with diagnosis of MPNs. Genic expression pro-
file was evaluated with Real-Time Polymerase Chain Reaction compared 
to mesenchymal human healthy cell line.
Results: We found that some markers known to be involved in angi-
ogenesis, as miR221, miR20a, HIF-1a and VEGF, are upregulated in 
BM-MSCs of MPNs patients. Regarding bone marrow fibrosis, expres-
sion analysis of THSB1, TGF-beta mRNAs and miR21 in BM-MSCs 
highlighted sensible upregulation in all samples, strongly suggesting a 
possible role of the MSCs in the mediation or induction of the fibrosis 
process in the bone marrow, in these diseases.
Summary/Conclusion: Our data suggest a possible role of the BM-
MSCs in fibrosis and neoangiogenesis in MPNs. In subgroup analysis, 
no significant differences were found between specific diseases (poly-
chythemia vera, essential thrombocytemia, myelfibrosis and MPN-un-
classifiable). Being driver mutations not enough to explain different 
clinical and histological presentations, it maybe that the study of the 
pathological MSCs will help comprehend the complex machine of 
pathogenesis in MPNs and possibly find new targets to develop drugs 
that may change the natural history of these diseases.
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Background: Recurrent somatic mutations in the JAK2, MPL, and 
CALR genes have been described in patients diagnosed with Philadel-
phia-negative Myeloproliferative neoplasms (MPNs), including Poly-
cythemia vera (PV), Essential thrombocythemia (ET) and Primary mye-
lofibrosis (PMF). MPN is also the most common etiology in splanchnic 
vein thrombosis (SVT). MPNs account for approximately 40% of Budd 
Chiari syndrome (BCS) and 31% of portal vein thrombosis (PVT).
The present study was aimed at studying the prevalence of JAK-2V617F, 
MPLW515L/K and CALR exon 9 mutations in BCR-ABL1 negative 
myeloproliferative neoplasms (MPNs) and splanchnic vein thrombosis 
(SVT) patients.There is paucity of such data in the Indian patients.
Aims: The study had two Aims:
1. Identification of incidence of JAK2V617F, CALR exon 9 mutations 
and MPLW515L/K mutations in BCR-ABL1 negative MPNs in India
2. Identification of incidence of JAK2V617F, CALR exon 9 mutations 
and MPLW515L/K mutations in Indian patients of SVT
Methods: A total number of 60 patients of SVT and 59 MPN patients (10 
PV, 19 ET, and 30 PMF) were included in the study. The mutation analysis 
for JAK2V617F, CALR exon 9 and MPLW515L/K mutations were per-
formed using the Allele specific oligonucleotide-polymerase chain reaction 
(ASO-PCR) was used to detect JAK-2, CALR and MPL mutations.
Results: Among 59 patients of MPNs and 60 SVT; JAK-2 mutation 
was found in 61.0% (36/59) and 23.3% (14/60) respectively. On 
sub-classification, JAK-2 mutation was detected in 80.0% (8/10) of 
PV; 42.1% (8/19) of ET and 66.7% (20/30) of PMF patients.
All the patients of MPNs and SVT were subjected to CALR mutation 
analysis. The overall rate of CALR mutations in PMF and ET was 
10% (3/30) and 21.0% (4/19) respectively. Limiting the analysis to 
JAK2V617F negative patients of PMF and ET, it was seen that 30% 
(3/10) PMF and ~36.36% (4/11) ET cases were CALR mutated. Of 
these 7 CALR mutations; L367fs*46 (type-1) and K385fs*47 (type-2) 
mutations were found in 5 and 2 patients respectively. MPL mutation 
was identified in 5.26% (1/19) ET cases. Triple negative ET and PMF 
were ~31.5% (~6/19) and ~23.3% (7/30) respectively. None of the 
SVT patients were observed to be CALR mutated and none showed the 
MPLW515L/K mutations.
Summary/Conclusion: Indian patients exhibit a lower incidence of 
CALR mutations in Primary myelofibrosis than that seen in the western 
literature. However, the incidence of CALR mutations is the same as 
that reported earlier in Indian patients of Essential thrombocythemia. 
Triple negative cases constitute 31.5% of all cases of Essential throm-
bocythemia and 23.3% of Primary myelofibrosis Indian patients show a 
Testing for CALR mutations and MPLW515L/K mutations in splanchnic 
vein thrombosis is not justified.
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Background: Primary myelofibrosis (PMF) is a Philadelphia negative 
myeloproliferativ neoplasm characterized by a clonal myeloid expansion 
which determines progressive bone marrow fibrosis resulting in ineffi-
cient hematopoiesis. Diagnosis is based both on bone marrow morphol-
ogy but also clinical aspects. There were described several mutations 
such as those in JAK2 V617F, MPL exon 10 and CALR exon 9 indel 
genes in aproximately 90% of the patients while the rest of 10% were 
so-called triple negative.
